Tag: Nasdaq:KRYS

Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsNasdaq:KRYS

ThroughPut.AI Now Available on SBIR Aisle of CDAO’s Tradewinds Solutions Marketplace

KrystoLens from Brain Navi Receives TFDA Certification, Set to Enter Taiwan Market

SweetNight Launches CoolNest® Pro, an Upgraded Memory Foam Mattress Engineered for Hot Sleepers

Tag: Nasdaq:KRYS

Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us